Insulin inhalation for diabetic patients: Nursing considerations

详细信息    查看全文

• 作者：Hanan Mohammed Mohammed^a ; ^{hanan.t2004@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; ^{hanant2004@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Rania Reafaat Abdelkader^b ; Manal Salah Hassan^a
• 关键词：HIIP ; Human Insulin Inhalation Powder ; FDA ; Food and Drug Administration ; AUC ; area under the curve ; FEV ; Forced Expiratory Volume ; COPD ; chronic obstructive pulmonary disease ; PFTs ; Pulmonary Function Tests ; T1DM ; Type1 Diabetes Mellitus ; T2DM ; Type2 Diabetes Mellitus ; BG ; Blood Glucose
• 刊名：Egyptian Journal of Chest Diseases and Tuberculosis
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：65
• 期：2
• 页码：531-535
• 全文大小：606 K

文摘

Scientific knowledge has advanced to enable the development of inhaled insulin. It is a form of diabetes medication administered via the pulmonary system that studies have shown to be efficacious in the treatment of both type 1 and type 2 diabetes. Inhaled insulin is a new, safe means to deliver insulin that may increase patient compliance with insulin therapy, helping them to achieve optimal glycemic control and possibly reducing their risk of developing cardiovascular complications. However, diabetes is a chronic illness requiring lifetime intervention. Empowering patients with the knowledge of the diabetes disease process may give them the confidence to be more autonomous in managing their diabetes. HIIP gives nurse practitioners a new option that may improve their patients’ acceptance of insulin therapy, and improve glycemic control.